葵花品牌怎么样 申请店铺

我要投票 葵花在中草药行业中的票数:780 更新时间:2026-01-08
葵花是哪个国家的品牌?「葵花」是 葵花药业集团股份有限公司 旗下著名品牌。该品牌发源于黑龙江,由创始人关玉秀在2005-09-07期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力葵花品牌出海!将品牌入驻外推网,定制葵花品牌推广信息,可以显著提高葵花产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

葵花怎么样

葵花药业集团是由其旗舰企业——黑龙江葵花药业股份有限公司,经过不断发展壮大组建起来的。下辖五常葵花、伊春葵花、重庆葵花、佳木斯葵花、佳木斯(鹿灵)葵花、唐山葵花、衡水葵花、衡水(冀州)葵花、哈尔滨葵花8家药品生产企业,两家医药公司,一个药材种植基地,一个药品包材公司,一个大药房共14家企业,总资产15.72亿元,总占地面积近百万平方米。总部位于哈尔滨市。董事长兼总裁关彦斌为全国劳动模范,第十一届、第十二届全国人大代表,中华全国工商联医药业商会常务副会长。

集团主营业务以中成药为主,同时涵盖化学药和生物药等,是集药品制造、营销、科研于一体。共拥有片剂、丸剂、散剂、栓剂、胶囊剂、合剂、颗粒剂、糖浆剂、软膏剂、浸膏剂、喷雾剂等15个剂型。目前,已形成以护肝片为代表的肝胆用药系列、以胃康灵和美沙拉嗪肠溶片为代表的胃肠用药系列、以小儿肺热咳喘口服液和小儿化痰止咳颗粒为代表的小葵花儿童用药系列、以康妇消炎栓和更年安片为代表的妇科用药系列、以双虎肿痛宁喷雾剂和加味天麻胶囊为代表的风湿骨病用药系列、以复方氨酚烷胺颗粒和感冒清热颗粒为代表的葵花蓝人呼吸感冒用药系列、以补虚通瘀颗粒和通脉颗粒为代表的心脑血管用药系列、以头孢克洛颗粒和阿莫西林胶囊为代表的抗生素用药系列等8大系列、724个准字号药品的产品新格局,其中3个国家中药保护品种,12个国内独家品种,被列入国家基本药物目录的产品就达179个。

经过十余年的品牌塑造,葵花品牌得到了消费者和行业客户的高度认可,“葵花”商标在2007年被国家工商总局商标局认定为“中国驰名商标”。小葵花儿童药在第五届“健康中国”2012中国药品品牌榜被评为第一品牌。

集团坚持“销售为龙头”的发展理念,现已建立了覆盖全国的营销网络,在各省会城市设立近两百个办事处,与全国近千家以上医药流通企业建立了良好稳定的合作关系,形成了以组合营销、控制营销、团队营销为特色的葵花营销模式。营销力做为引擎强力拉动着企业的发展,截至2011年,已连续7年位居哈尔滨市民营企业纳税第一名。

在科技研发上,实施生产一批、储备一批、研发一批的战略,曾成功研发了以护肝片、胃康灵胶囊为代表的全国知名中药产品,为我国中药事业的发展做出了突出贡献。集团通过建立完善研发管理体系,通过“买、改、联、研”多种途径提高企业创新发展能力。集团设立科技研发中心,各生产企业设立科研所,以雄厚的经济实力和人才优势,先后投资1亿多元进行新产品研发,其中护肝滴丸和双参乙肝滴丸研发已取得了显著成果,护肝滴丸被列入国家863计划,双参乙肝滴丸被列为省科技攻关项目。

在企业发展历程中,形成了以“两个基本点”和“三个子系统”为基本架构模式的葵花文化。两个基本点:一是“责任”,即“产业报国,贡献社会,受益员工”的企业价值观;二是“诚信”,即“诚实做人,诚实做事,诚信永恒”的经营理念。三个子系统:即文化方向系统、文化定位系统和文化路径系统。“两个基本点”通过“三个子系统”的具体化导入,使企业的文化理念又与企业的发展战略、组织架构、规章制度等有机结合,形成了具有葵花特色的管理文化体系,成为企业管理的制导系统,更是企业生存与发展的灵魂与基因。

集团现为全国工商联直属会员企业、中国中药协会会员单位、国家火炬计划重点高新技术企业,全国中成药行业50强企业。先后获得“全国五一劳动奖状”、“全国就业与社会保障先进民营企业”、“全国守合同重信用企业”、“全国实施卓越绩效模式先进企业”、“全国民营企业政治思想工作先进单位”、“全国企业文化建设优秀单位”、“全国双爱双评先进企业”、“全国模范职工之家”等荣誉称号。

黑龙江葵花药业股份有限公司为全国大型中成药生产企业,被中国中药协会、中国医药报社联合评为“2010年中药企业品牌百强”、“中药成长型优秀企业品牌”企业。

按照集团的战略发展规划,集团计划于2018年,葵花组建20周年之际,建造一个规模百亿的、以医药产业为主的葵花航母战斗群,并以此为基础,实现组织集团化、产业配套化、资本社会化、产品系列化、技术高端化、经营国际化,努力打造一个享誉百年的世界级品牌,为社会的发展与人类的健康做出更大的贡献。

Sunflower Pharmaceutical Group is established by its flagship enterprise, Heilongjiang sunflower Pharmaceutical Co., Ltd. through continuous development and expansion. Under the jurisdiction of Wuchang sunflower, Yichun sunflower, Chongqing sunflower, Jiamusi sunflower, Jiamusi (Luling) sunflower, Tangshan sunflower, Hengshui sunflower, Hengshui (Jizhou) sunflower and Harbin sunflower, there are eight pharmaceutical production enterprises, two pharmaceutical companies, one herbal medicine planting base, one pharmaceutical packaging company and one large pharmacy with a total assets of 1.572 billion yuan, covering an area of nearly 100 Ten thousand square meters. The headquarter is located in Harbin. Guan Yanbin, chairman and President, is a national model worker, deputy to the 11th and 12th National People's Congress, and executive vice president of all China Federation of industry and Commerce medical and pharmaceutical chamber of Commerce. The main business of the group is Chinese patent medicine, covering chemical medicine, biological medicine, etc. it integrates drug manufacturing, marketing and scientific research. There are 15 formulations: tablet, pill, powder, suppository, capsule, mixture, granule, syrup, ointment, extract and spray. At present, there have been salad series of liver and gall, represented by liver protecting tablets, gastrointestinal medicine series represented by Wei Kang Ling and mesalazine enteric coated tablets, a series of small sunflower children represented by Xiaoer Fei rekxiao oral liquid and Xiaoer Huatan Zhike granule, a series of gynecological drugs represented by Kang Fu Xiaoyan suppository and Gannan tablets, with double tiger swelling pain spray and Jiawei Tianma capsule. The new product patterns of 8 series and 724 quasi brand drugs, such as rheumatic bone disease drug series, sunflower blue people's respiratory cold drug series represented by compound paracetamol and Ganmao Qingre granules, cardiovascular and cerebrovascular drug series represented by Buxu Tongyu granules and Tongmai Granules, antibiotic drug series represented by cefaclor granules and Amoxicillin Capsules, etc There are 3 national protected varieties of traditional Chinese medicine, 12 domestic exclusive varieties, and 179 products listed in the national basic drug catalog. After more than ten years of brand building, sunflower brand has been highly recognized by consumers and industry customers, "sunflower" trademark was recognized as "China famous trademark" by the Trademark Office of the State Administration for Industry and Commerce in 2007. Xiaokui Huaer children's medicine was rated as the first brand in the fifth "healthy China" 2012 Chinese medicine brand list. The group adheres to the development concept of "sales as the leader", has established a nationwide marketing network, set up nearly 200 offices in each provincial capital city, established good and stable cooperative relations with more than 1000 pharmaceutical circulation enterprises nationwide, and formed a sunflower marketing mode characterized by combination marketing, control marketing and team marketing. As an engine, the marketing force is driving the development of enterprises. As of 2011, it has been ranked first in the tax payment of private enterprises in Harbin for seven consecutive years. In terms of scientific and technological research and development, we have implemented the strategy of producing, reserving and developing a batch of products. We have successfully developed famous Chinese medicine products represented by Hugan tablet and Weikangling capsule, which have made outstanding contributions to the development of Chinese medicine in China. Through the establishment and improvement of R & D management system, the group improves the innovation and development ability of enterprises through various ways of "purchase, reform, joint research". The group has set up scientific and technological research and development centers, and each production enterprise has set up scientific research institutes. With strong economic strength and talent advantages, it has invested more than 100 million yuan in the research and development of new products, among which the research and development of liver protecting dropping pills and double ginseng hepatitis B dropping pills have made remarkable achievements. Liver protecting dropping pills have been listed in the National 863 plan, and double ginseng hepatitis B dropping pills have been listed as the provincial scientific and technological research projects. In the course of enterprise development, sunflower culture has formed with "two basic points" and "three subsystems" as the basic structure mode. There are two basic points: one is the enterprise values of "responsibility", that is, "industry serves the country, contributes to the society, benefits employees"; the other is "integrity", that is, the business philosophy of "being honest, doing things honestly, integrity is eternal". Three subsystems: cultural orientation system, cultural orientation system and cultural path system. "Two basic points" through the specific introduction of "three sub-systems", make the enterprise's cultural concept and the enterprise's development strategy, organizational structure, rules and regulations, etc. organic combination, formed a management culture system with sunflower characteristics, become the guidance system of enterprise management, is the soul and gene of enterprise survival and development. The group is now a member enterprise directly under the all China Federation of industry and commerce, a member unit of China Association of traditional Chinese medicine, a key high-tech enterprise under the national torch plan, and one of the top 50 enterprises in the Chinese patent medicine industry. It has successively won the "National May 1st Labor Award", "national employment and social security advanced private enterprise", "national contract abiding and trustworthy enterprise", "national implementation of outstanding performance model advanced enterprise", "national private enterprise political and ideological work advanced unit", "national enterprise culture construction excellent unit", "national double love and double evaluation advanced enterprise", "national model post "Home of work" and other honorary titles. Heilongjiang sunflower Pharmaceutical Co., Ltd. is a large-scale Chinese patent medicine manufacturer in China. It has been jointly appraised as "top 100 Chinese medicine enterprises in 2010" and "excellent enterprise brand of Chinese medicine growth type" by China Association of traditional Chinese medicine and China Pharmaceutical News Agency. According to the group's strategic development plan, the group plans to build a 10 billion scale sunflower aircraft carrier battle group with the pharmaceutical industry as the main industry in 2018 on the 20th anniversary of the establishment of sunflower. Based on this, the group will realize the organizational collectivization, industrial supporting, capital socialization, product seriation, high-end technology and international operation, and strive to build a world-class product with a reputation of 100 years Brand, for social development and human health to make greater contributions.

本文链接: https://brand.waitui.com/07573b81c.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

具身机器人也有自己的保单,险企竞逐机器人保险业务

机器人租赁市场需求旺盛,也催生了大量的保险保障需求。多位业内人士认为,机器人保险作为新型保险产品,其发展成熟需要大量的数据支撑,如果仅与单一企业合作或投保单一设备,数据积累会比较慢。通过与租赁平台等合作,不仅可以获得批量保单,也有利于实现数据的快速积累,为精算定价、风险理赔提供数据支撑,机器人保险有望迎来新增长极。不过,机器人保险在我国还处在起步阶段,发展过程中的风险评估难、产品适配差、责任界定难、风控能力弱等问题,还需要多方协作、共同破局。(上证报)

2小时前

日本11月份实际工资同比下降2.8%,为去年1月以来最大降幅

日本政府周四公布的初步数据显示,受一次性奖金大幅减少的拖累,日本11月份实际工资出现了自去年1月以来的最大降幅。与此同时,通胀超过工资增长的潜在趋势没有改变,这给日本央行带来了挑战。此前日本央行已发出信号,将在今年继续加息。(新浪财经)

2小时前

机构称2026年铜市上行趋势明朗

2025年年末,国内铜现货(电解铜)价格突破100000元/吨关口,为铜市注入强劲动力。与此同时,2026年长单签订博弈进入白热化,国内提价潮、外贸溢价攀升、铜精矿加工费(TC/RC)低位僵持等现象集中出现。业内人士表示,这既反映出市场对供需格局的预判,也预示着2026年铜价或开启新一轮上涨行情。(中证网)

2小时前

中信建投:商业航天产业有望进入新纪元

36氪获悉,中信建投指出,当前商业航天产业在国家政策支持和产业技术突破共同助力下,有望进入新纪元。商业航天产业涉及信息化的主要环节包括(1)遥感及其应用;(2)卫星测运控系统;(3)CAE仿真/卫星测试;(4)星际传输处理模块、通信模组、数据处理平台等;新场景扩展层面关注太空算力。此外,我们认为当前商业航天发展是国企与民营企业共振周期。

2小时前

耐心资本布局硬科技,社保科创基金多地落子

长期资本正在重塑科技创新领域的投资生态。全国社会保障基金理事会官网显示,目前已成立的5只社保科创基金定位均为“服务国家发展的市场化基金”,旨在疏通金融资源进入实体经济的渠道,增加支持科技创新和产业创新深度融合的有效投资,在服务科技强国建设、助力科创企业成长中实现基金安全和保值增值。多位专家介绍,从浙江首发到江苏、福建、湖北、四川相继跟进,社保科创基金的迅速布局,标志着国家长期、耐心资本与区域创新战略的系统性对接已进入加速布局阶段。(上证报)

2小时前

本页详细列出关于葵花的品牌信息,含品牌所属公司介绍,葵花所处行业的品牌地位及优势。
咨询